Halozyme Therapeutics (HALO) said Wednesday that Johnson & Johnson (JNJ) unit Janssen-Cilag International received European Commission approval for an indication extension of Darzalex co-formulated with Halozyme's Enhanze drug delivery technology to treat adults newly diagnosed with multiple myeloma.
The latest approval covers people with the disease regardless of transplant eligibility, Halozyme said.
Halozyme's Enhanze drug delivery technology is used for the subcutaneous delivery of injected drugs, the company said.
Halozyme shares were 1% lower in early trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。